

ASX Market Announcements
ASX Limited
Level 4
North Tower, Rialto
525 Collins Street
Melbourne VIC 3000

RE: Release of Restricted Securities from Escrow

In connection with the quotation of Adherium Limited's fully paid ordinary shares (**Shares**) on the Australian Securities Exchange (**ASX**) on 26 August 2015 certain security holders in the Company were required to enter into ASX imposed restriction agreements and/or voluntary escrow agreements. These agreements restricted the relevant security holders from dealing in their securities for periods of up to 24 months from the date of quotation.

In accordance with ASX Listing Rule 3.10A, the Company advises that 146,870 fully paid ordinary shares of the Company will be released from ASX imposed restriction on 14 December 2015.

Application for quotation of these 146,870 fully paid ordinary shares will also be made following their release from restriction.

Kind regards



Rob Turnbull
Joint Company Secretary

ASX: ADR**ABN**

24 605 352 510

Company Overview

Adherium is a global leader in digital health technologies which address sub optimal medication use in chronic disease.

Directors

Dr J Doug Wilson (Chair)
Mr Garth Sutherland (Group CEO)
Prof. John Mills
Mr Jeremy Curnock Cook
Mr Bruce McHarrie
Mr Bryan Mogridge

Joint Company Secretaries

Mr Rob Turnbull
Ms Bronwyn Le Grice

Registered Office

Level 12, 15 William Street
Melbourne VIC 3000
Australia

NZ Office

Level 2, 204 Quay Street
Auckland 1010
New Zealand

Investor Relations Contact

Ms Bronwyn Le Grice
+61 424 862 600

Email

investors@adherium.com

Website

www.adherium.com